Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

10x Genomics delivers powerful ... The site will feature a new state-of-the-art genomics lab scheduled to open in early 2024. Proteintech Genomics, a subsidiary of Proteintech Group, inc., and a ...

(see more details here) A team of medical professionals in surgical scrubs analysing research data in a laboratory. 10x Genomics, Inc. (NASDAQ:TXG) is a U.S.-based life science technology company.

Shares of companies in the lab-tool equipment sector, including Bruker (NASDAQ:BRKR), Illumina (NASDAQ:ILMN), Quanterix ...

Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...

In addition, the lab provides and routinely employs the full suite of 10x Genomics single-cell applications, including gene expression; VDJ sequencing, TotalSeq feature barcoding and cell hashing ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...